Tenaya Therapeutics, Inc (TNYA) Files up to $100M IPO

Tenaya Therapeutics, Inc (NASDAQ: TNYA) has filed for an up to $100,000,000 IPO.

The company describes itself as: "We are a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, the leading cause of death in the world, and in doing so improve and extend the lives of millions of individuals and families. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with both rare and highly prevalent forms of heart disease."

Morgan Stanley, Cowen, Piper Sandler and Chardan will serve as underwriters.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Futuremain to merge with ChampionsGate in $80M Nasdaq deal
• Allarity Therapeutics files SPAC registration for $100M IPO